ストックスクリーナーアプリを入手
30.13
0.65%
0.195
前日終値:
$29.93
開ける：
$30.26
24時間の取引高:
1.45M
Relative Volume:
0.51
時価総額：
$3.75B
収益：
$715.22M
当期純損益:
$-250.10M
株価収益率:
-14.84
EPS:
-2.03
ネットキャッシュフロー:
$-205.58M
1週間 パフォーマンス:
+8.81%
1か月 パフォーマンス:
-9.27%
6か月 パフォーマンス:
-20.67%
1年 パフォーマンス:
-52.77%
1日の値動き範囲:
$29.39
$30.52
1週間の範囲:
$28.25
$30.52
52週間の値動き範囲:
$24.34
$71.90
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
名前
Apellis Pharmaceuticals Inc
セクター
電話
617-977-5700
住所
100 FIFTH AVENUE, WALTHAM, KY
APLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
30.13 | 3.75B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-17 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-21 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-16 | 開始されました | William Blair | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Neutral |
| 2024-02-05 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-02 | 開始されました | Mizuho | Neutral |
| 2023-10-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-15 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 繰り返されました | Citigroup | Buy |
| 2023-08-03 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-08-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-19 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-17 | 再開されました | Stifel | Buy |
| 2022-04-14 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-09-10 | 繰り返されました | Credit Suisse | Neutral |
| 2021-09-10 | 繰り返されました | Needham | Buy |
| 2021-09-10 | 繰り返されました | Oppenheimer | Outperform |
| 2021-09-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-08-19 | 開始されました | Jefferies | Buy |
| 2021-08-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2020-11-19 | 開始されました | Needham | Buy |
| 2020-09-01 | 開始されました | Stifel | Buy |
| 2020-07-20 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-04-01 | 開始されました | Raymond James | Strong Buy |
| 2020-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-11 | アップグレード | Wedbush | Underperform → Neutral |
| 2020-01-07 | 開始されました | SVB Leerink | Mkt Perform |
| 2019-12-19 | 開始されました | BofA/Merrill | Buy |
| 2019-11-22 | 開始されました | Wedbush | Underperform |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-08-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-07-30 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-04-12 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
Apellis Pharmaceuticals chief medical officer sells shares worth $55,512 - Investing.com India
Apellis Pharmaceuticals CCO Adam Townsend sells $65,937 in stock By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals CCO Adam Townsend sells $65,937 in stock - Investing.com India
Apellis Pharmaceuticals CFO Timothy Sullivan sells $51,827 in stock - Investing.com India
Apellis Pharmaceuticals VP sells $21,420 in stock - Investing.com India
Apellis Pharmaceuticals executive sells $36,998 in stock By Investing.com - Investing.com Australia
Apellis Pharmaceuticals executive sells $36,998 in stock - Investing.com India
Apellis Pharmaceuticals chief scientific officer sells $22,468 in stock - MSN
Apellis Pharmaceuticals CEO Francois sells shares worth $179,958 - MSN
Apellis Pharmaceuticals general counsel sells shares valued at $65,937 - MSN
Apellis Pharmaceuticals chief people officer sells shares worth $37,178 - Investing.com
Analyst Expectations For Apellis Pharmaceuticals's Future - Benzinga
Royal Bank of Canada Reiterates Sector Perform Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Up 7.3% in December - MarketBeat
Hennion & Walsh Asset Management Inc. Buys 17,115 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
IC-MPGN Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Novartis, Apellis Pharmaceuticals - The Globe and Mail
IC-MPGN Market Revenue to Expand Significantly by 2034, States - openPR
HC Wainwright Reiterates Buy Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect - AccessWire
Apellis Pharmaceuticals, Inc. Reports Financial Results and Board ChangesWALTHAM, MA–(GLOBE NEWSWIRE)–Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) recently disclosed preliminary unaudited total U.S. net product revenues for the fourth quarter a - Defense World
Apellis Pharmaceuticals CEO Cedric Francois sells shares worth $179,302 By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals chief people officer sells $45,894 in stock By Investing.com - Investing.com Australia
Apellis Pharmaceuticals VP sells shares worth $22,473 By Investing.com - Investing.com Canada
Apellis Pharmaceuticals chief scientific officer sells $65,670 in stock - Investing.com India
Apellis Pharmaceuticals chief scientific officer sells $65,670 in stock By Investing.com - Investing.com Australia
Apellis Pharmaceuticals CFO sells shares worth $62,283 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals chief development officer sells shares worth $7,577 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells $62,279.00 in Stock - MarketBeat
David O. Watson Sells 4,965 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharmaceuticals CTO Nicholson Nur sells shares worth $75,543 By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals officer sells shares worth $77,065 By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals general counsel sells shares worth $142,505 By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals CTO Nicholson Nur sells shares worth $75,543 - Investing.com India
Apellis Pharmaceuticals officer sells shares worth $77,065 - Investing.com India
Apellis Pharmaceuticals CFO sells shares worth $62,283 - Investing.com
Apellis Pharmaceuticals chief people officer sells $45,894 in stock - Investing.com India
James George Chopas Sells 783 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $179,288.90 in Stock - MarketBeat
Apellis Pharmaceuticals CEO Cedric Francois sells shares worth $179,302 - Investing.com
Apellis Pharmaceuticals chief business officer sells shares totaling $45,894 - Investing.com
Apellis Pharmaceuticals VP sells shares worth $22,473 - Investing.com
Apellis Pharmaceuticals chief development officer sells shares worth $7,577 - Investing.com India
Apellis Pharmaceuticals Inc (APLS) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):